secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001104659-24-042231
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa plans Phase 2b trial of abiprubart in Sjogren's Disease; reports RA Cohort 4 data
--------------------------------------------------------------------------------

- Phase 2b trial in Sjogren's Disease to initiate 2H 2024; 201 patients, 24-week placebo-controlled, primary endpoint ESSDAI.
- Cohort 4 RA data: abiprubart 400 mg SC monthly showed DAS28-CRP LS mean difference -0.58 vs placebo (p=0.109, not significant).
- Statistically significant ~40% reduction in Rheumatoid Factor in Cohort 4 (p=0.0003); pooled analysis DAS28-CRP diff -0.52 (nominal p=0.010).
- Abiprubart development in Sjogren's fully funded through Phase 3; company expects to remain cash flow positive annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924042231/0001104659-24-042231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924042231/tm249997d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-042231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer